BioSpace News Archive

Histogen Inc. (NASDAQ: HSTO), announced today that it has entered into securities purchase agreements with certain institutional and accredited investors to issue, in a private placement, 8,235,297 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 8,235,297 shares of common stock.

Nkarta, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NKX101 for treatment of acute myeloid leukemia (AML).

Gracell Biotechnologies Inc. today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI).

Hybrid imaging is fusion of two or more imaging technologies into a single new form. The image obtained with hybrid imaging system is more powerful in terms of accuracy as compared to two single images.

Cardiovascular diseases are a major cause of death across the globe. According to the World Health Organization, the number of deaths caused by these diseases is expected to surpass 23 million by 2030.

Blood culture tests are conducted when a healthcare provider suspects that a patient might suffer from blood infection.

Alpine Immune Sciences, Inc. (Nasdaq: ALPN) and Horizon Therapeutics plc (Nasdaq: HZNP) today announced an exclusive license and collaboration agreement for the development and commercialization of up to four preclinical candidates generated from Alpine’s unique discovery platform.

Arcturus Therapeutics Holdings Inc. today announced new data and updates from clinical development programs for ARCT-154 and ARCT-165.

Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced certain preliminary financial results for the second fiscal quarter ended November 30, 2021.

Neuvivo, Inc., a company developing clinical-stage treatments for ALS and other neurodegenerative diseases, announced that it has submitted to the FDA a request for a Type C meeting to solicit feedback on the proposed development pathway for its lead candidate, NP001, for the treatment of ALS.